Dewpoint Therapeutics, Inc. — Form D/A

Dewpoint Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2026-07-13. The offering totals $82.3M, of which $77.2M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (40)

Showing 25 of 40 people.

NameRoleLocation
Srinivas Akkaraju, M.D., Ph.D.Related PersonBoston, MA
Regina Barzilay, Ph.D.Related PersonBoston, MA
Olivier Brandicourt, M.D.Related PersonBoston, MA
Giuseppe A. Ciaramella, Ph.D.Related PersonBoston, MA
Anthony A. Hyman, Ph.D.Related PersonBoston, MA
Isaac A. Klein, M.D., Ph.D.Related PersonBoston, MA
Mark Murcko, Ph.D.Related PersonBoston, MA
Amir H. Nashat, Sc.D.Related PersonBoston, MA
Ameet Nathwani, M.D.Related PersonBoston, MA
Steven Neier, Ph.D.Related PersonBoston, MA
Richard A. Young, Ph.D.Related PersonBoston, MA
Regina Barzilay, Ph.D.DirectorBoston, MA
Guiseppe A Ciaramella, Ph,D.DirectorBoston, MA
Mark A Murcko, Ph.D.DirectorBoston, MA
Amir H Nashat, Ph.D.DirectorBoston, MA
Olivier Brandicourt, M.D.DirectorBoston, MA
Elisabeth A LeidermanExecutive OfficerBoston, MA
Ameet Nathwani, M.D.DirectorBoston, MA
Ameet Nathwani, M.D.Executive OfficerBoston, MA
Isaac A Klein, M.D., Ph.D.Executive OfficerBoston, MA
Srinivas Akkaraju, M.D., Ph.D.DirectorBoston, MA
Lori A EscobedoExecutive OfficerBoston, MA
Fabio H Pucci, Ph.D.DirectorBoston, MA
Anthony A Hyman, Ph.D.DirectorBoston, MA
Giuseppe H Ciaramella, Ph.D.DirectorBoston, MA

Other filings by this issuer (3)

FiledFormOfferingSold
2025-09-23D$59.1M$59.1M
2022-02-04D$150.0M$150.0M
2020-11-02D$77.1M$77.1M

More